Why the study?
Cardiotoxic effects limit the clinical use of doxorubicin, and the role of DDX3X in doxorubicin-induced cardiotoxicity remains unclear.
DDX3X plays a protective role against doxorubicin-induced cardiotoxicity in vitro by activating Wnt/β-catenin signaling, suggesting a potential therapeutic target.
DDX3X modulation merits exploration in doxorubicin cardiotoxicity; hypothesis-generating and requires in vivo confirmation before any clinical consideration.
The life-threatening adverse effects of doxorubicin (Dox) caused by its cardiotoxic properties limit its clinical application. DDX3X has been shown to participate in a variety of physiological processes, and it acts as a regulator of Wnt/β-catenin signaling. However, the role of DDX3X in Dox-induced cardiotoxicity (DIC) remains unclear. In this study, we found that DDX3X expression was significantly decreased in H9c2 cardiomyocytes treated with Dox. Ddx3x knockdown and RK-33 (DDX3X ATPase activity inhibitor) pretreatment exacerbated cardiomyocyte apoptosis and mitochondrial dysfunction induced by Dox treatment. In contrast, Ddx3x overexpression ameliorated the DIC response. Moreover, Wnt/β-catenin signaling in cardiomyocytes treated with Dox was suppressed, but this suppression was reversed by Ddx3x overexpression. Overall, this study demonstrated that DDX3X plays a protective role in DIC by activating Wnt/β-catenin signaling.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2022) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: